Clearance of imidapril, an angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: Comparison with quinapril and enalapril

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 259-263

  Tsuruoka, Shuichi ^a   Kitoh, Yasuhiko ^a   Kawaguchi, Atsuhiro ^a   Sugimoto, Koh Ichi ^a   Hayasaka, Tokie ^b   Saito, Tetsuo ^b   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Moka Hospital   (Japan)

Author keywords

Dialyzability; Enalapril; Hemodialysis; Imidapril; Quinapril

Indexed keywords

CONAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; IMIDAPRIL; QUINAPRIL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PROTEIN BINDING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLIDINES; KIDNEY FAILURE; MALE; RENAL DIALYSIS; TETRAHYDROISOQUINOLINES;

EID: 33846424544     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293751     Document Type: Article

References (19)

1. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999 ; 33: 507-517.
2. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998 ; 32: S5 - S13.
3. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000 ; 58: 2147-2154.
4. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002 ; 61: 2157-2164.
5. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis. 2002 ; 40: 1023-1029.
6. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002 ; 62: 1784-1790.
7. Guidelines Subcommittee of the Japanese Society of Hypertension. Japanese Society of Hypertension Guideline for the Management of Hypertension (JSH2004). Tokyo, Japan: Lifescience Publication ; 2004.
8. Taeschner W, Vozeh S. Pharmocokinetic drug data. In: Speight T, Holford N, eds. Avery's Drug Treatment. Auckland, New Zealand: Adis International ; 1997: 1629-1664.
9. Kelly JG, Doyle GD, Carmody M, Glover DR, Cooper WD. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Br J Clin Pharmacol. 1988 ; 26: 781-786.
10. Blum RA, Olson SC, Kohli RK, Horvath AM, Sedman AJ, Posvar EL. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis. J Clin Pharmacol. 1990 ; 30: 938-942.
11. Saruta T, Omae T, Kuramochi M, et al. Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens. 1995 ; 13 (suppl 3). 523-530.
12. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet. 1993 ; 24: 230-254.
13. Interview Form of Imidapril. Osaka, Japan: Tanabe Seiyaku Co Ltd; 2004.
14. Gabutti L, Taminelli-Beltraminelli L, Marone C. Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers. Eur J Clin Pharmacol. 1997 ; 53: 123-126.
15. Tsuruoka S, Sugimoto KI, Hayasaka T, Saito T, Fujimura A. Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. Eur J Clin Pharmacol. 2000 ; 56: 581-583.
16. Harder S, Thurmann PA, Ungethum W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol. 1998 ; 45: 377-380.
17. Peterson R, Peterson L. Cleansing the blood: hemodialysis, peritoneal dialysis, exchange transfusion, chalcoal hemoperfusion, forced diuresis. Pediatr Clin North Am. 1986 ; 33: 675-689.
18. Maher J. Pharmacological considerations for renal failure and dialysis. In: Maher J, ed. Replacement of Renal Failure by Dialysis. Dordrecht, the Netherlands: Kluwer Academic Publishers ; 1989: 1018-1076.
19. Authority of the United States Pharmacopeial Convention. Drug Information for the Health Care Professional. New York, NY: Willston ; 2001.